Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target

Gene: ANXA2

Summary for ANXA2

Gene information	Gene symbol	ANXA2
	Ensembl ID	ENSG00000182718
	Entrez ID	302
	Gene name	annexin A2
	Synonyms	ANX2\|ANX2L4\|CAL1H\|LIP2\|LPC2D
	Gene type	protein_coding
	UniProtAcc	P07355

Top

Dataset with differentially expressed gene: ANXA2

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE140440	DU145 and PC cell lines	Cell line	Prostate cancer	Prostate cancer	Chemotherapy	docetaxel	NA	Malignant cells	0.589966	5.97e-15
GSE186960	Panc1 cell line	Cell line	Pancreatic cancer	Pancreatic ductal adenocarcinoma (PDAC)	Chemotherapy	gemcitabine	NA	Malignant cells	-0.548728	0.00e+00
GSE138267	CDX	Tumor tissue	Lung cancer	Small cell lung cancer (SCLC)	Chemotherapy	NA	NA	Malignant cells	1.47886	0.00e+00
GSE163836	FCIBC02 cell line	Cell line	Breast cancer	Inflammatory breast cancer	Chemotherapy	paclitaxel	NA	Malignant cells	-0.309056	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	CD8+ T cells	0.355352	1.28e-40
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	cDCs	0.471274	1.64e-08
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Mono/Macro	-0.349808	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	cDCs	0.907354	5.86e-22
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	Mono/Macro	1.23187	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Mono/Macro	0.978592	0.00e+00
GSE153697	patients	Bone marrow aspirate	Acute lymphoblastic leukemia	Relapsed B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	anti-CD19 CAR-T	NA	Malignant cells	-0.988244	0.00e+00
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	Mono/Macro	0.477056	0.00e+00
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	cDCs	0.791998	1.30e-28
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	Mono/Macro	0.315715	6.79e-04
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD8+ T cells	0.423893	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	B cells	0.399337	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	Mono/Macro	0.385454	5.10e-15
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD4+ T cells	0.446188	0.00e+00
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	post	CD8+ T cells	0.315909	0.00e+00
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	Mono/Macro	-0.744119	0.00e+00
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Malignant cells	0.493157	2.16e-08
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	Malignant cells	0.733503	0.00e+00
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	Malignant cells	-0.276064	0.00e+00
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	cDCs	-0.650264	3.14e-42
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	pre	Malignant cells	-0.386843	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	NK cells	0.802407	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD8+ T cells	0.496913	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	B cells	1.19756	2.72e-03
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD4+ T cells	0.580625	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	Malignant cells	-0.724626	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	CD4+ T cells	-0.314457	2.78e-03
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	post	NK cells	0.3346	3.08e-15
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	pre	Malignant cells	0.322676	0.00e+00
GSE131984_Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	palbociclib	NA	Malignant cells	-0.328675	1.63e-11
GSE108397	451Lu cell line	Cell line	Melanoma	Melanoma	Targeted therapy	PLX-4720	NA	Malignant cells	0.601558	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	CD4+ T cells	-0.357232	1.14e-03
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	Malignant cells	-0.522982	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	Malignant cells	0.296792	0.00e+00
GSE175716	PDX	Tumor tissue	Liver cancer	Advanced hepatocellular carcinoma	Targeted therapy	sorafenib	NA	Malignant cells	-1.27748	0.00e+00
GSE115251	Kelly cell line	Cell line	Neuroblastoma	Neuroblastoma	Targeted therapy	TAE684	NA	Malignant cells	0.384778	0.00e+00
GSE164897_Vem	A375 cell line	Cell line	Melanoma	BRAFV600E-mutant melanoma	Targeted therapy	vemurafenib	NA	Malignant cells	0.442635	0.00e+00

Top

Expression of ANXA2 in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to ANXA2

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Gene symbol	Mechanism
ANXA2	Unusual Activation of Pro-survival Pathway

Page: 1

Top

MicroRNAs (miRNA) regulating ANXA2

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
ANXA2	hsa-miR-8054	94.6795	NM_001002857
ANXA2	hsa-miR-548k	94.6795	NM_001002857
ANXA2	hsa-miR-548av-5p	94.6795	NM_001002857
ANXA2	hsa-miR-1-3p	88.6495	NM_001002857
ANXA2	hsa-miR-206	88.6495	NM_001002857
ANXA2	hsa-miR-5696	86.9832	NM_004039
ANXA2	hsa-miR-613	86.1058	NM_001002857
ANXA2	hsa-miR-548ar-5p	81.391	NM_001002857

Page: 1

Top

Motifs and transcription factors (TFs) regulating ANXA2

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
ANXA2	taipale_tf_pairs__E2F1_HES7_RRCRCGYGYNNNNSGCGCSN_CAP_repr	E2F1; HES7 (directAnnotation).
ANXA2	kznf__ZNF25_Imbeault2017_OM_MEME	ZNF25 (directAnnotation).
ANXA2	taipale_tf_pairs__ETV5_HES7_NNCACGTGNNNNCCGGAANN_CAP	ETV5; HES7 (directAnnotation).
ANXA2	kznf__ZNF777_Imbeault2017_RP_ChIP-seq	ZNF777 (directAnnotation).
ANXA2	metacluster_67.2	ZNF501 (directAnnotation). ACAA1; E2F2; E2F2; E2F3; E2F3; FOXN4 (inferredBy_Orthology).
ANXA2	metacluster_3.14	WT1; WT1 (directAnnotation).
ANXA2	swissregulon__hs__ZBTB14	ZBTB14 (directAnnotation).
ANXA2	cisbp__M07938	E2F1 (directAnnotation).
ANXA2	transfac_pro__M07397	ZNF148 (directAnnotation).
ANXA2	taipale_cyt_meth__ZNF281_NCCCCTCCCCCN_eDBD_meth	ZNF281 (directAnnotation).
ANXA2	metacluster_15.2	E2F1; E2F1; E2F1; E2F1; E2F1; E2F3; E2F4; E2F4; E2F4; E2F6; E2F6; E2F6; E2F6; E2F6; E2F6; E2F6; E2F7; TFDP1; TFDP2; ZNF566; ZNF566; ZNF574 (directAnnotation). E2F3; E2F3; E2F4 (inferredBy_Orthology).
ANXA2	metacluster_7.13	ZFX (directAnnotation).
ANXA2	metacluster_3.11	SP1; SP1; SP2; SP3; SP3; SP4 (directAnnotation).
ANXA2	transfac_pro__M01175	ZBTB7B (directAnnotation).
ANXA2	taipale_cyt_meth__ZNF460_NRMCGCCCCCCGN_eDBD_meth	ZNF460 (directAnnotation).
ANXA2	tfdimers__MD00151	CHURC1 (directAnnotation).
ANXA2	metacluster_3.7	SP1; SP1; SP1; SP1; SP1; SP1; SP1; SP1; SP2; SP2; SP2; SP2; SP3; SP3; SP3; SP4; SP4; SP4; SP4; SP4; SP4; SP5 (directAnnotation).
ANXA2	transfac_pro__M01303	SP1 (directAnnotation).
ANXA2	metacluster_141.5	NR3C1; THAP1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY2; YY2; ZNF597 (directAnnotation). YY1; YY1; YY1; YY2; ZFP42 (inferredBy_Orthology).
ANXA2	transfac_pro__M01714	KLF15 (directAnnotation).
ANXA2	hocomoco__PROX1_HUMAN.H11MO.0.D	PROX1 (directAnnotation).
ANXA2	transfac_pro__M02089	E2F3 (directAnnotation).
ANXA2	hocomoco__EGR4_HUMAN.H11MO.0.D	EGR4 (directAnnotation).
ANXA2	metacluster_3.5	KLF14; KLF15; KLF15; KLF16 (directAnnotation).
ANXA2	transfac_pro__M02281	SP1 (directAnnotation).
ANXA2	kznf__ZNF730_Imbeault2017_RP_RCADE	ZNF730 (directAnnotation).
ANXA2	transfac_pro__M02898	SMAD3 (directAnnotation).
ANXA2	transfac_public__M00491	PATZ1 (directAnnotation).
ANXA2	transfac_pro__M07461	KLF1; KLF10; KLF11; KLF12; KLF13; KLF15; KLF16; KLF17; KLF2; KLF3; KLF4; KLF5; KLF6; KLF7; KLF8; KLF9 (directAnnotation).
ANXA2	kznf__ZNF594_Schmitges2016_RCADE	ZNF594 (directAnnotation).
ANXA2	kznf__ZBTB14_Schmitges2016_RCADE	ZBTB14 (directAnnotation).
ANXA2	transfac_pro__M04617	ZBTB7A (directAnnotation).
ANXA2	taipale_cyt_meth__E2F2_NCGCGCGCGCM_eDBD_meth	E2F2 (directAnnotation).
ANXA2	transfac_pro__M07387	ZBTB7A (directAnnotation).
ANXA2	transfac_pro__M00716	ZBTB14 (directAnnotation).
ANXA2	metacluster_170.2	KLF1; KLF10; KLF10; KLF11; KLF11; KLF11; KLF12; KLF12; KLF14; KLF15; KLF17; KLF2; KLF5; KLF7; KLF7; KLF8; MAZ; MAZ; PATZ1; SP1; SP1; SP1; SP2; SP2; SP2; SP2; SP2; SP2; SP2; SP2; SP4; SP4; SP5; SP6; SP7; SP8; SP9; ZNF281 (directAnnotation). E2F1; E2F4; KLF10; KLF13; KLF14; KLF17; KLF2; KLF7; SP1; SP1; SP3; SP4; SP5; SP6; SP7 (inferredBy_Orthology).
ANXA2	transfac_pro__M03876	ZBTB33 (directAnnotation).
ANXA2	metacluster_133.1	ZNF304; ZNF304; ZSCAN22 (directAnnotation).
ANXA2	taipale_cyt_meth__CREB1_NRTGACGTN_eDBD_repr	CREB1 (directAnnotation).
ANXA2	transfac_pro__M01783	SP2 (directAnnotation).
ANXA2	metacluster_155.23	BCL11B; ZNF711; ZNF711 (directAnnotation). ZFY (inferredBy_Orthology).
ANXA2	cisbp__M00341	PAX6 (directAnnotation).
ANXA2	transfac_pro__M01253	CNOT3 (directAnnotation).
ANXA2	homer__TWVGGTCCGC_HINFP	HINFP (directAnnotation).
ANXA2	transfac_pro__M04817	ZBTB33 (directAnnotation).
ANXA2	transfac_pro__M00803	E2F1; E2F3; E2F4; TFDP1 (directAnnotation).
ANXA2	kznf__ZNF548_Imbeault2017_RP_RCADE	ZNF548 (directAnnotation).
ANXA2	metacluster_22.29	NFE2 (directAnnotation).
ANXA2	metacluster_22.12	NFE2; NFE2L1 (directAnnotation).
ANXA2	metacluster_22.25	NFE2L2 (directAnnotation).

Page: 1 2 3 4 5

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

Target name	Drug name	Drug ID	Drug type
ANXA2	"Artenimol"	DB11638	small molecule
ANXA2	"Fluocinolone acetonide"	DB00591	small molecule
ANXA2	"Lanoteplase"	DB06245	biotech
ANXA2	"Tenecteplase"	DB00031	biotech

Page: 1

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."